Accessibility Menu
MetaVia logo

MetaVia

(NASDAQ) MTVA

Current Price$1.80
Market Cap$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-76%
1 Month+9%
MetaVia last closing stock price
MetricPriceDate
Last closeUSD 1.802026-07-16
MetaVia stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.05%USD 1.732026-07-09
1 month+9.09%USD 1.652026-06-16
3 month+28.57%USD 1.402026-04-17
Year to date-78.62%USD 8.422025-12-31
1 year-75.71%USD 7.412025-07-16
3 year-95.33%USD 38.562023-07-17
5 year-99.98%USD 7,207.202021-07-16
Since inception-99.99%USD 23,100.022019-12-31

MetaVia Financials at a Glance

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.13M

EPS (TTM)

-$6.02

P/E Ratio

-0.30

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$1.80

Volume

4,915

Open

$1.83

Previous Close

$1.80

Daily Range

$1.76 - $1.85

52-Week Range

$0.97 - $19.03

Estimated Earnings Date

Aug 6, 2026

MTVA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MetaVia

MetaVia develops medicines for liver and metabolic diseases. Its drugs aim to help people with obesity or liver problems. The company’s treatments target conditions that affect millions worldwide.

What’s in the Medicine Cabinet?

  • Vanoglipel (DA-1241): Oral drug in trials for fatty liver disease and type 2 diabetes; no revenue contribution yet.
  • DA-1726: Injectable therapy in early testing for obesity; no revenue contribution yet.
  • Legacy Programs: Includes treatments for COVID-19, nerve pain, and memory loss; not actively developed or generating revenue.
  • Gemcabene: Licensed from Pfizer for cholesterol disorders; not yet commercialized.
  • Research Partnerships: Collaborates with Dong-A ST and ImmunoForge for drug development.

Growth Spurts and Strategic Moves

  • Out-licensed NB-01 for nerve pain to MThera Pharma in July 2024.
  • Secured exclusive global licenses (excluding Korea) from Dong-A ST for lead drugs in 2022.
  • Closed $9.1 million private placement with Dong-A ST and Dong-A Holdings in May 2025.
  • Completed Phase 2a trial for vanoglipel in November 2024; topline results announced December 2024.
  • Closed $9.3 million public offering in January 2026 to fund operations.

Why MetaVia Catches the Eye

MetaVia focuses on first-in-class drugs for liver and metabolic diseases. Its partnerships with larger pharmaceutical companies provide access to new compounds and manufacturing. The company’s patent portfolio protects its main drug candidates through at least 2041.

Five Things You Need to Know

  • Reported $0 revenue for 2025, 2024, and 2023; no product sales yet.
  • Net loss was $13.0 million in 2025, improving 53% from 2024.
  • Cash and equivalents were $10.3 million at December 31, 2025, down 36% year-over-year.
  • R&D expenses fell 68% to $6.8 million in 2025 from 2024.
  • Management sees substantial doubt about continuing as a going concern into late 2026.

Bottom Line

MetaVia has shifted focus to liver and metabolic disease drugs, relying on partnerships and licensing. The company remains pre-revenue and faces ongoing funding challenges as it advances clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Hyung-Heon Kim

Website

metaviatx.com

Headquarters

Cambridge, MA 02138, US

MTVA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-172.92%

Return on Capital

-247.30%

Return on Assets

-91.22%

Earnings Yield

-3.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.16M

Volume

4.92K

Avg. Volume

3.91M

Financials (TTM)

Gross Profit

-$15.00K

Operating Income

-$13.85M

EBITDA

-$13.11M

Operating Cash Flow

-$15.14M

Capital Expenditure

-$2.00K

Free Cash Flow

-$15.15M

Cash & ST Invst.

$13.73M

Total Debt

$194.00K

MetaVia Performance Analysis

MetaVia annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
MetaVia sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
MetaVia annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -477.57-72.6%
20232023-12-31USD -27.05-94.3%
20242024-12-31USD -39.1344.7%
20252025-12-31USD -7.35-81.2%
MetaVia sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3027.8%
Q32025-09-3046.2%
Q42025-12-3145.5%
Q12026-03-316.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.00K

-25.0%

Gross Margin

0.00%

N/A

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.16M

N/A

Employees

8

N/A

Net Income

-$3.82M

-4.1%

EBITDA

-$3.82M

-4.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.73M

+22.7%

Total Debt

$194.00K

+64.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$123.00K

+232.4%

Short Term Debt

$71.00K

-12.3%

Return on Assets

-91.22%

N/A

Return on Invested Capital

-1.51%

N/A

Free Cash Flow

-$4.26M

+11.6%

Operating Cash Flow

-$4.26M

+11.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
XCURExicure, Inc.
$1.62+0.00%
NCNANuCana plc
$1.33-1.48%
CLGNCollPlant Biotechnologies Ltd.
$0.34-2.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NOKNokia
$10.38-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.74-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.89+0.05%

Questions About MTVA

What is the current price of MetaVia?

MetaVia is trading at $1.80 per share.

What is the 52-week range for MetaVia?

Over the past 52 weeks, MetaVia has traded between $0.97 and $19.03.

How much debt does MetaVia have?

As of the most recent reporting period, MetaVia reported total debt of $194.00K.

How much cash does MetaVia have on hand?

MetaVia reported $13.73M in cash and cash equivalents in its most recent financial results.

What is MetaVia’s dividend yield?

MetaVia does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services